1. Home
  2. ALT vs SCM Comparison

ALT vs SCM Comparison

Compare ALT & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • SCM
  • Stock Information
  • Founded
  • ALT 1997
  • SCM 2012
  • Country
  • ALT United States
  • SCM United States
  • Employees
  • ALT N/A
  • SCM N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • SCM Finance/Investors Services
  • Sector
  • ALT Health Care
  • SCM Finance
  • Exchange
  • ALT Nasdaq
  • SCM Nasdaq
  • Market Cap
  • ALT 333.6M
  • SCM 397.8M
  • IPO Year
  • ALT N/A
  • SCM 2012
  • Fundamental
  • Price
  • ALT $3.93
  • SCM $12.13
  • Analyst Decision
  • ALT Strong Buy
  • SCM Hold
  • Analyst Count
  • ALT 6
  • SCM 1
  • Target Price
  • ALT $17.40
  • SCM $13.00
  • AVG Volume (30 Days)
  • ALT 3.0M
  • SCM 242.3K
  • Earning Date
  • ALT 11-11-2025
  • SCM 11-06-2025
  • Dividend Yield
  • ALT N/A
  • SCM 13.19%
  • EPS Growth
  • ALT N/A
  • SCM 11.71
  • EPS
  • ALT N/A
  • SCM 1.43
  • Revenue
  • ALT $20,000.00
  • SCM $102,761,445.00
  • Revenue This Year
  • ALT N/A
  • SCM N/A
  • Revenue Next Year
  • ALT N/A
  • SCM $1.23
  • P/E Ratio
  • ALT N/A
  • SCM $8.45
  • Revenue Growth
  • ALT N/A
  • SCM N/A
  • 52 Week Low
  • ALT $2.90
  • SCM $11.19
  • 52 Week High
  • ALT $11.16
  • SCM $15.56
  • Technical
  • Relative Strength Index (RSI)
  • ALT 52.80
  • SCM 22.98
  • Support Level
  • ALT $3.85
  • SCM $12.18
  • Resistance Level
  • ALT $4.06
  • SCM $13.25
  • Average True Range (ATR)
  • ALT 0.20
  • SCM 0.27
  • MACD
  • ALT 0.02
  • SCM -0.18
  • Stochastic Oscillator
  • ALT 57.35
  • SCM 6.74

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

Share on Social Networks: